FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer By Ogkologos - June 17, 2026 245 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved two companion diagnostics for identifying patients for treatment with fam-trastuzumab deruxtecan-nxki Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR A tribute to Dame Valerie Beral October 13, 2022 Can cancer cells communicate? February 28, 2023 Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up August 5, 2025 ΚΑΡΚΙΝΟΣ ΠΑΓΚΡΕΑΤΟΣ November 22, 2018 Load more HOT NEWS Mom Of Three Fought Breast Cancer, Drought, And Australia Bushfires In... FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High... For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target EMA Recommends Granting a Marketing Authorisation Under Exceptional Circumstances for Moxetumomab...
